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Background: Infections with bovine herpesvirus 1 (BoHV-1) and bovine viral diarrhoea (BVD) virus cause diseases of
cattle with a worldwide distribution. The primary objective of the present study was to describe aspects of herd-level
BoHV-1 and BVDV seroprevalence (based on testing of pooled sera) and control on farms in Northern Ireland, including
vaccine usage.
An indirect antibody ELISA test (SVANOVA, Biotech AB, Uppsala, Sweden) was applied to serum pools which
were constructed from serum samples taken for a cross-sectional study of a convenience sample of 500 Northern Irish
dairy and beef cow herds in 2010, for which vaccination status was determined by telephone survey. The herd-level
seroprevalence of BoHV-1 and BVDV in Northern Ireland was estimated in non-vaccinating herds and associations
between possible risk factors (herd type and herd size (quartiles)) and herd-level prevalence were determined
using chi-squared analysis.
Results: The herd-level seroprevalence (of BoHV-1 and BVDV) in non-vaccinating herds was 77.3% (95% CI: 73.6–80.9%)
and 98.4% (95% CI: 97.3–99.5%) respectively in the cross-sectional study. A significant difference existed in BoHV-1
herd-level seroprevalence between dairy and beef herds (74.7% vs 86.5% respectively; p < 0.02) though not for BVDV
seroprevalence (98.5% vs 98.3% respectively; p > 0.91). A significant association was found between herd size (quartiles)
and herd-level classification for BoHV-1 herd-level seroprevalence based on cut-off percentage positivity (COPP) (p < 0.01)
while no such association was found for BVDV (p = 0.22).
15.5% and 23.8% of farmers used BoHV-1 and BVDV vaccines, respectively. BoHV-1 vaccine was used in 30% of
dairy herds and in 11% of beef herds, while BVDV vaccine was used in 46% and 16% of dairy and beef herds,
respectively.
Conclusions: The results from this study indicate that the true herd-level seroprevalences to bovine herpesvirus 1 and
bovine virus diarrhoea virus in non-vaccinating herds in Northern Northern Ireland are 77.3% (95% CI: 73.6–80.9%) and
98.4% (95% CI: 97.3–99.5%), respectively. The present study will assist in guiding regional policy development and establish
a baseline against which the progress of current and future control and eradication programmes can be measured.* Correspondence: bosco.cowley@merck.com
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Bovine herpesvirus-1 (BoHV-1) and bovine viral diarrhoea
virus (BVDV) cause infectious diseases of cattle with a
worldwide distribution [1,2]. A number of Member States
within the European Union (EU) have either successfully
eradicated these infections or are currently implementing
voluntary or compulsory programmes. Herd-level anti-
body prevalence of each infection shows a wide variation
between countries. Strategies for their control and eradi-
cation have been previously reviewed [1,3].
In Northern Ireland, limited information is available
regarding BoHV-1 infection, albeit from a biased subset
of outbreaks [4]. While more information is available
regarding seroprevalence of BVDV, this research was re-
stricted to dairy herds. Approximately 90% of those herds
were classified with higher grouping for seropositivity,
while 5.4% were positive for viral antigen [5]. Furthermore
it is some time since this work was conducted. As yet,
herd-level prevalence has not been evaluated for either for
beef or dairy herds for BoHV-1 or for beef herds for
BVDV, and data are not available concerning strategies
(including vaccination) being used to control these infec-
tions in Northern Ireland. An understanding of the preva-
lence of these diseases and vaccine usage in their control
is necessary for designing and implementing effective
national control measures. A number of Member States
within the European Union (EU) are considered free of
BoHV-1 including Denmark, Germany (the Federal State
of Bavaria), Italy (the Province of Bolzano), Austria,
Finland, and Sweden [6] while Norway and Switzerland
are also considered free [7]. Other countries have EU
accredited eradication programmes for BoHV-1 in place
(Czech Republic, Germany (all regions, except the Federal
State of Bavaria), and Italy (the Autonomous Region of
Friuli Venezia Giulia, the Autonomous Province of Trento)
[6]. Several other European countries have national control
programmes that are not yet accredited by EU legislation.
Similarly for BVDV eradication, programmes have been
completed or are well-advanced in Scandinavia, Austria
and Switzerland. Compulsory national programmes are
also underway in Germany and Republic of Ireland and
regional eradication programmes have been implemented
in France and in the UK (Scotland, Shetland, Orkney and
Northern Ireland) [8].
This study describes aspects of BoHV-1 and BVDV in-
fections and their control on farms in Northern Ireland,





As part of the national statutory brucellosis eradication
scheme, serum samples are collected annually from alleligible animals (female bovines and entire bulls aged
12 months or over) in all cattle herds in Northern
Ireland and tested by the Agri-food and Biosciences
Institute (AFBI). A sample of these herds was selected
for the current study. Two herd types were defined in
this study–beef (containing >66% beef breed animals)
and dairy (containing >66% dairy breed animals). Small
herds were excluded (herds <10 breeding cattle). The
aim was to select a total sample size of 500 to allow for
selection of sufficient herds based on herd-level Se and
Sp of tests when used on serum pools and a herd level
prevalence of 70% [9].
Samples were received by the AFBI during a ten week
period from July to September 2010. Throughout the
study period, animals were mostly kept on managed
grassland. Permission for inclusion in the study was sought
from all selected herdowners. The sera were stored, ran-
domly selected, used to construct serum pools and subse-
quently analysed using indirect ELISA tests for BoHV-1
and BVDV antibodies (SVANOVA, Biotech AB, Uppsala,
Sweden) respectively in AFBI as described in previous
studies [9,10]. Herds under brucellosis restrictions are
placed under a more intense testing regime but were
excluded from the study.
Vaccine usage survey
A phone survey was used to clarify BoHV-1 and BVDV
vaccine usage in each of the study herds. Where rele-
vant, at least three attempts were made to contact each
study herd keeper. National vaccine usage data were
obtained from GfK Kynetec, an international market
research company that gathers data on sales of animal
health products [11]. In Northern Ireland, GfK sales data
are derived from the main veterinary wholesaler, who dis-
tributes all BoHV-1 and BVDV vaccine. Using Microsoft
Excel 2003, the data were summarised according to the
number of vaccine doses sold by time of application
(month) within Northern Ireland.
Data analysis
Vaccine usage
Among the study herds, vaccine usage by seasonality
and herd type were evaluated. Vaccine usage in study
herds was compared to regional usage data.
Seroprevalence study
Pooled serum: The optical density result of each serum
pool was recorded. The optimal cut-off PP values (COPP),
as determined in earlier studies (by conducting Receiver
Operating Characteristics Analysis on replicate results of a
preliminary validation study [9,10]), were used to clas-
sify each pool as seropositive or negative for BoHV-1
and BVDV, respectively. The prevalences among non-
vaccinated herds were separately evaluated. Apparent
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the proportion of positive pools [12]. Associations were
evaluated between herd-level seroprevalence classification
(based on COPP) and the following parameters: herd type
and herd size (quartiles) using a chi-square test.Results
Vaccine usage
Interviews were conducted with all of the study herd
owners. No information on BoHV-1 and BVDV vaccin-
ation history was available for 2.8% and 3.4%, respect-
ively. Data regarding BoHV-1 and BVDV vaccine usage
and by herd type are presented in Table 1. Throughout
all of Northern Ireland, approximately 550,000 doses of
BoHV-1 and 376,000 doses of BVDV vaccine were used
in 2010 [11], with a distinctly seasonal pattern of usage.
Vaccination in study herds showed a similar seasonal
pattern (Figure 1a-b) to overall vaccine usage in Northern
Ireland [11].Figure 1 Monthly vaccine usage on 501 Northern Irish farms
and regionally during 2010. a. shows BoHV-1 vaccine; b. shows
BVD vaccine.Seroprevalence study
Pooled serum
Samples from 501 herds were collected during the
study period of which 74.6% were classified as beef and
25.4% were dairy, comprising 50,600 animals including
25,800 cows (females > 2 years old). These farms repre-
sented just under 2.4% of all beef and dairy herds in
Northern Ireland. The exclusion of small herds (con-
taining <10 eligible animals) represented less than 1%
of dairy cows, but almost 12% of beef cows [13]. Ex-
cluding the 3.4% of herds where no vaccination history
was available, herd-level prevalence for BoHV-1 and
BVDV in non-vaccinating herds was 77.3% (95% CI:
73.6–80.9%) and 98.4% (95% CI: 97.3–99.5%), respect-
ively. Herd-level classification by herd type is outlined
in Table 2 (excluding vaccinating herds and herds with
unknown vaccination history). Herd-level seroprevalence
values differed significantly between dairy and beef herds
for BoHV-1 (74.7% vs 86.5%; p < 0.02) though not for
BVDV (98.5% vs 98.3%; p > 0.91). A significant association
was found between herd size (quartiles) and herd-level
seroprevalence classification for BoHV-1 based on cut-off
percentage positivity (COPP) (p < 0.01) while no such
association was found for BVDV (p = 0.22) (Table 3).Table 1 Vaccination usage by herd type (herds with no
vaccination history excluded)
Herd type
% of herds using vaccine
BoHV-1 BVDV
Beef 11 16
Dairy 30 46Discussion and conclusions
Apparent herd-level prevalence of BoHV-1 and BVDV
in non-vaccinating herds in Northern Ireland was 77.3%
(95% CI: 73.6–80.9%) and 98.4% (95% CI: 97.3–99.5%),
respectively.
National herd-level seroprevalence expressed as a per-
centage of positive herds depends on the selected cut-off,
which in turn depends on estimated within-herd preva-
lence. Cut-off selection and issues relating to sample
pooling have been discussed previously [9,10]. Herd classi-
fication is based on pooled tests in the seroprevalence
study. Because pooling creates complexity, it was assumed
that the sensitivity and specificity of the tests when used
on the pools was equivalent to these parameters when
used on individual sera. However, it is likely that the
pooled sensitivity would be lower than single sample sen-
sitivity, especially when within-herd prevalence is low and
pool size is large. Individual animals with prolonged sero-
positivity, along with these other factors, would mitigate
any effect on pooled sensitivity. The specificity of a pooled
sample should exceed that of an individual sample
because of dilution, as discussed previously [9,10].
Prior to the present study, only limited information
was available on herd-level prevalence of BoHV-1 or
BVDV in the Northern Irish bovine herd, or on vaccine
usage at farm level. Herd-level seroprevalences found in
Table 2 Herd level serological classification percentage by herd type
Herd type
Herd level serological classification %
BoHV-1 negative BoHV-1 positive BVDV negative BVDV positive
Beef 25.3 74.7 1.7 98.3
Dairy 13.5 86.5 1.5 98.5
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Republic of Ireland [9,10], though comparisons may not
be viable as there are significant differences in the source
of animals and the regulatory framework between these
regions.
Control measures within the current bovine brucellosis
control programme in Northern Ireland include annual
testing of all herds except some dairy herds which are
sampled biennially. Herd testing is coordinated by the
local divisional veterinary offices and performed within
three months of the overdue date ensuring that the pro-
gress of the overall sampling programme is distributed
evenly across Northern Ireland. Sampling bias could have
arisen due to the convenience sampling model employed
in this study rather than true randomized sampling. How-
ever, randomization would not suit the model for brucel-
losis testing implemented in Northern Ireland and as this
scheme provided a ready source of samples, this method-
ology provided the most efficient and cost-effective means
of collection of samples from a large number of herds in a
short time.
The distinctly seasonal usage of BVDV vaccine (spring
and autumn/winter peaks with lower amounts in summer)
reflects the calving pattern of the Northern Irish herd,
suggesting that most vaccine is used prior to breeding as
per manufacturers’ recommendations. Most BoHV-1 vac-
cine is used in the autumn suggesting usage prior to win-
ter housing. Conventional and marker BoHV-1 vaccines
are currently marketed. However the licensed duration of
immunity of all BoHV-1 vaccines is six months. Lack of
compliance with licensed recommendations may have
an impact on the success of vaccination in control. The
majority of vaccine is used in dairy herds (Table 1), despite
herd-level seroprevalence being higher in dairy herds than
beef for BoHV-1 and similar in both herd types for BVDV.
Herd level seroprevalence was also found to be signifi-
cantly higher in larger herds for BoHV-1 though not forTable 3 Herd level serological classification percentage by he
Herd size
Herd le





p < 0.01BVDV. The latter result is likely to be because herd-level
seroprevalence is almost 100%, which precludes differenti-
ation between positive and negative herds on the basis of
size. Recall bias could have arisen in this study among
farmers surveyed. Vaccine brand used was determined to
minimize recall bias and confusion with vaccines used to
control other diseases.
Economic losses from BoHV-1 and BVDV infections
have been reviewed previously [14,15]. Northern Ireland
has a cattle population comprising approximately 281,000
dairy cows and 258,000 beef cows. Significant differences
exist in farm size evolution between these two sectors in
the 10 year period from 2000 onwards. The average dairy
herd size has increased from 54 cows to 77 cows during
this period while the average beef herd size has declined
from 19 to 17 cows [16]. As a result, significant disease
control challenges lie ahead for the dairy sector in Northern
Ireland. Current BoHV-1 controls are limited almost exclu-
sively to vaccination, a strategy which, if used alone, is
unlikely to have a significant impact in an area of high
herd-level prevalence [1]. There are currently no plans
to eradicate BoHV-1 in Northern Ireland. A move to
prohibit the authorization and use of conventional
(non-marker) BoHV-1 vaccines would be a useful ini-
tial step towards implementing an eradication scheme
at some point in the future considering the current
high herd level prevalence of this disease and vaccine
usage [1]. A voluntary programme to identify and elimin-
ate animals persistently infected (PI) with BVD virus,
through tissue tagging of calves, began in January 2013
with the goal of progressing to a compulsory programme
in 2014. This programme mirrors that already in place in
the Republic of Ireland, from which lessons may be
learned [17]. Additional measures such as certification of
herds and implementation of biosecurity measures may be
required to make any impact on herd-level seroprevalence
for these diseases in Northern Ireland considering therd size (quartiles)
vel serological classification %
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cessary for the design and implementation of effective
concerted national control and eradication measures.
Furthermore, efforts to increase awareness of these dis-
eases and encourage implementation of cost-effective
controls, including screening, elimination of PI animals,
vaccination and biosecure practices will help reduce
prevalence. However, ultimately these must be coupled
with statutory measures to effectively reduce national
prevalence. Control of either disease in Northern Ireland
will be best effected by cross-border collaboration between
the newly formed Animal Health and Welfare Northern
Ireland (AHWNI; www.animalhealthni.com) and Animal
Health Ireland (AHI; www.animalhealthireland.ie), industry
bodies charged with the national leadership and
co-ordination of programmes to address production
diseases in Northern Ireland and Republic of Ireland
respectively.
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